T. Kurosaki, K. Kometani, and W. Ise, Memory B cells, Nat Rev Immunol, vol.15, pp.149-59, 2015.

S. L. Nutt, P. D. Hodgkin, D. M. Tarlinton, and L. M. Corcoran, The generation of antibody-secreting plasma cells, Nat Rev Immunol, vol.15, pp.160-71, 2015.

K. Basso and R. Dalla-favera, Germinal centres and B cell lymphomagenesis, Nat Rev Immunol, vol.15, pp.172-84, 2015.

R. Kuppers, Mechanisms of B-cell lymphoma pathogenesis, Nat RevCancer, vol.5, pp.251-62, 2005.

L. R. Teras, C. E. Desantis, J. R. Cerhan, L. M. Morton, A. Jemal et al., US lymphoid malignancy statistics by World Health Organization subtypes. Q13 CA, Cancer J Clin, 2016.

T. Kuwana, L. Bouchier-hayes, J. E. Chipuk, C. Bonzon, B. A. Sullivan et al., BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly, Mol Cell, vol.17, pp.525-560, 2005.

T. J. Mcdonnell, N. Deane, F. M. Platt, G. Nunez, U. Jaeger et al., bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation, Cell, vol.57, pp.79-88, 1989.

R. Beroukhim, C. H. Mermel, D. Porter, G. Wei, S. Raychaudhuri et al., The landscape of somatic copy-number alteration across human cancers, Nature, vol.463, pp.899-905, 2010.

H. Tagawa, S. Karnan, R. Suzuki, K. Matsuo, X. Zhang et al., Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM, Oncogene, vol.24, pp.1348-58, 2005.

A. Cimmino, G. A. Calin, M. Fabbri, M. V. Iorio, M. Ferracin et al., miR-15 and miR-16 induce apoptosis by targeting BCL2, Proc Natl Acad Sci, vol.102, pp.13944-13953, 2005.

E. S. Raveche, E. Salerno, B. J. Scaglione, V. Manohar, F. Abbasi et al., Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice, Blood, vol.109, pp.5079-86, 2007.

J. Huang, W. Fairbrother, and J. C. Reed, Therapeutic targeting of Bcl-2 family for treatment of B-cell malignancies, Exp Rev Hematol, vol.8, pp.283-97, 2015.

G. Lessene, P. E. Czabotar, and P. M. Colman, BCL-2 family antagonists for cancer therapy, Nat Rev Drug Discov, vol.7, pp.989-1000, 2008.

C. Touzeau, C. Dousset, L. Gouill, S. Sampath, D. Leverson et al., The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma, Leukemia, vol.28, pp.210-212, 2014.

C. Touzeau, L. Gouill, S. Mahe, B. Boudreault, J. S. Gastinne et al., Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14), Haematologica, vol.102, pp.112-126, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01445538

H. Dai, X. W. Meng, and S. H. Kaufmann, Mitochondrial apoptosis and BH3 mimetics. F1000Research, vol.5, p.2804, 2016.

M. S. Davids, A. W. Roberts, J. F. Seymour, J. M. Pagel, B. S. Kahl et al., Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma, J Clin Oncol, vol.35, pp.826-859, 2017.

A. W. Roberts, M. S. Davids, J. M. Pagel, B. S. Kahl, S. D. Puvvada et al., Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia, N Eng J Med, vol.374, pp.311-333, 2016.

J. D. Leverson, D. Sampath, A. J. Souers, S. H. Rosenberg, W. J. Fairbrother et al., Found in translation: how preclinical research is guiding the clinical development of the BCL2-selective inhibitor venetoclax, Cancer Discov, vol.7, pp.1376-93, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01638832

S. Kumar, J. L. Kaufman, C. Gasparetto, J. Mikhael, R. Vij et al., Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma, Blood, vol.130, pp.2401-2410, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01631468

M. S. Davids, Targeting BCL-2 in B-cell lymphomas, Blood, vol.130, pp.1081-1089, 2017.

N. Tsuyama, S. Sakata, S. Baba, Y. Mishima, N. Nishimura et al., BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation, Blood, vol.130, pp.489-500, 2017.

D. Chiron, C. Bellanger, A. Papin, B. Tessoulin, C. Dousset et al., Rational targeted therapies to overcome microenvironmentdependent expansion of mantle cell lymphoma, Blood, vol.128, pp.2808-2826, 2016.

C. Dousset, S. Maiga, P. Gomez-bougie, L. Coq, J. Touzeau et al., BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma, Br J Haematol, vol.179, pp.684-692, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01353369

S. K. Tahir, M. L. Smith, P. Hessler, L. R. Rapp, K. B. Idler et al., Potential mechanisms of resistance to venetoclax and strategies to circumvent it, BMC Cancer, vol.17, p.399, 2017.

S. H. Swerdlow, E. Campo, S. A. Pileri, N. L. Harris, H. Stein et al., The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood, vol.127, pp.2375-90, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01800015

K. Tarte, J. M. Veyrune, J. L. Berberich, I. Fiol, G. Redal et al., The Bcl2 family member Bfl-1/A1 is strongly repressed in normal and malignant plasma cells but is a potent anti-apoptotic factor for myeloma cells, Br J Haematol, vol.125, pp.373-82, 2004.
URL : https://hal.archives-ouvertes.fr/inserm-00368387

V. A. Gupta, S. M. Matulis, J. E. Conage-pough, A. K. Nooka, J. L. Kaufman et al., Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma, Blood, vol.129, pp.1969-79, 2017.

R. Thijssen, E. Slinger, K. Weller, C. R. Geest, T. Beaumont et al., Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors, Haematologica, vol.100, pp.302-308, 2015.

X. S. Puente, P. Jares, and E. Campo, Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions, Blood, vol.131, pp.2283-96, 2018.

J. Iqbal, V. T. Neppalli, G. Wright, B. J. Dave, D. E. Horsman et al., BCL2 expression is a prognostic marker for the activated B-celllike type of diffuse large B-cell lymphoma, J Clin Oncol, vol.24, pp.961-969, 2006.

P. L. Bergsagel, W. M. Kuehl, F. Zhan, J. Sawyer, B. Barlogie et al., Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma, Blood, vol.106, pp.296-303, 2005.
DOI : 10.1182/blood-2005-01-0034
URL : http://www.bloodjournal.org/content/106/1/296.full.pdf

A. Broyl, D. Hose, H. Lokhorst, Y. De-knegt, J. Peeters et al., Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients, Blood, vol.116, pp.2543-53, 2010.

F. Zhan, Y. Huang, S. Colla, J. P. Stewart, I. Hanamura et al., The molecular classification of multiple myeloma, Blood, vol.108, pp.2020-2028, 2006.

P. L. Bergsagel and W. M. Kuehl, Molecular pathogenesis and a consequent classification of multiple myeloma, J Clin Oncol, vol.23, pp.6333-6341, 2005.

R. Szalat, H. Avet-loiseau, and N. C. Munshi, Gene expression profiles in myeloma: ready for the real world?, Clin Cancer Res, vol.22, pp.5434-5476, 2016.

P. Gomez-bougie and M. Amiot, Apoptotic machinery diversity in multiple myeloma molecular subtypes, Front Immunol, vol.4, p.467, 2013.
DOI : 10.3389/fimmu.2013.00467
URL : https://www.frontiersin.org/articles/10.3389/fimmu.2013.00467/pdf

S. Montoto and J. Fitzgibbon, Transformation of indolent B-cell lymphomas, J Clin Oncol, vol.29, 2011.
DOI : 10.1200/jco.2010.32.7577

D. Chiron, C. Dousset, C. Brosseau, C. Touzeau, S. Maiga et al., Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma, Oncotarget, vol.6, pp.8750-8759, 2015.

P. Gomez-bougie, M. S. Tessoulin, B. Bourcier, J. Bonnet, A. Rodriguez et al., BH3-mimetic toolkit guides the respective use of BCL2 Q13 and MCL1 BH3-mimetics in myeloma treatment, Blood, 2018.

M. Vogler, M. Butterworth, A. Majid, R. J. Walewska, X. M. Sun et al., Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately Q18 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia, Blood, vol.113, pp.4403-4416, 2009.

J. Bodo, X. Zhao, L. Durkin, A. J. Souers, D. C. Phillips et al., Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells, Oncotarget, vol.7, pp.70000-70010, 2016.
DOI : 10.18632/oncotarget.12132
URL : http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=12132&path%5B%5D=38390

M. Vogler, H. S. Walter, and M. Dyer, Targeting anti-apoptotic BCL2 family proteins in haematological malignancies-from pathogenesis to treatment, Br J Haematol, vol.178, pp.364-79, 2017.
DOI : 10.1111/bjh.14684
URL : https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.14684

C. M. Adams, R. Mitra, J. Z. Gong, and C. M. Eischen, Non-hodgkin and hodgkin lymphomas select for overexpression of BCLW, Clin Cancer Res, vol.23, pp.7119-7148, 2017.
DOI : 10.1158/1078-0432.ccr-17-1144
URL : http://clincancerres.aacrjournals.org/content/clincanres/23/22/7119.full.pdf

J. E. Chipuk and D. R. Green, PUMA cooperates with direct activator proteins to promote mitochondrial outer membrane permeabilization and apoptosis, Cell Cycle, vol.8, pp.2692-2698, 2009.
DOI : 10.4161/cc.8.17.9412
URL : http://europepmc.org/articles/pmc3228357?pdf=render

M. Papatriantafyllou, B cells: secrets to plasma cell longevity, Nat Rev Immunol, vol.13, pp.156-163, 2013.
DOI : 10.1038/nri3410

S. Wuilleme-toumi, N. Robillard, P. Gomez, P. Moreau, L. Gouill et al., Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival, Leukemia, vol.19, pp.1248-52, 2005.

I. E. Wertz, S. Kusam, C. Lam, T. Okamoto, W. Sandoval et al., Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7, Nature, vol.471, pp.110-114, 2011.

Q. Zhong, W. Gao, F. Du, and X. Wang, Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis, Cell, vol.121, pp.1085-95, 2005.

C. Brosseau, C. Dousset, C. Touzeau, S. Maiga, P. Moreau et al., Combination of lenalidomide with vitamin D3 induces apoptosis in mantle cell lymphoma via demethylation of BIK, Cell Death Dis, vol.5, 2014.

A. C. Queiros, R. Beekman, R. Vilarrasa-blasi, M. Duran-ferrer, G. Clot et al., Decoding the DNA methylome of mantle cell lymphoma in the light of the entire B cell lineage, Cancer Cell, vol.30, pp.806-827, 2016.

M. Zhang, Z. Y. Xu-monette, L. Li, G. C. Manyam, C. Visco et al., RelA NF-kappaB subunit activation as a therapeutic target in diffuse large B-cell lymphoma, Aging, vol.8, pp.3321-3361, 2016.

J. Moreaux, B. Klein, R. Bataille, G. Descamps, S. Maiga et al., A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines, Haematologica, vol.96, pp.574-82, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00550232

A. Tarte and K. , The yin and the yang of follicular lymphoma cell niches: role of microenvironment heterogeneity and plasticity, Semin Cancer Biol, vol.24, pp.23-32, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-00866220

K. Balakrishnan, J. A. Burger, M. Fu, T. Doifode, W. G. Wierda et al., Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia, Neoplasia, vol.16, pp.1036-1082, 2014.

A. Papin, L. Gouill, S. Chiron, and D. , Rationale for targeting tumor cells in their microenvironment for mantle cell lymphoma treatment, Leuk Lymph, vol.59, pp.1064-72, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-01655227